{"url_path":"/sec/dtil/8-k/2026-07-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1357874/0001628280-26-046340-index.html","accession_number":"0001628280-26-046340","cik":"0001357874","ticker":"DTIL","issuer_name":"PRECISION BIOSCIENCES INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1357874/0001628280-26-046340-index.html","primary_entity_key":"0001357874","primary_entity_name":"PRECISION BIOSCIENCES INC"},"word_count":366,"has_tables":true,"body_markdown":"Item 8.01 Other Events\n\nIn its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The Company is targeting year-end 2026 for the next program update.\n\nAlso in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy with initial safety data targeted for year-end 2026.\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding expected program or data update, and commencement of the FUNCTION-DMD clinical trial. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2026, as such factors may be updated from time to time in the Company’s other filings with the Securities and Exchange Commission (“SEC”), which filings are accessible on the SEC’s website at www.sec.gov and the Investors & Media page of the Company’s website. All forward-looking statements speak only as of the date of this Current Report on Form 8-K, and except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise."}